v3.25.4
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2026
Jan. 31, 2025
Jul. 31, 2025
Cash flow from operating activities          
Net loss for the period $ (7,296,893) $ (6,337,828) $ (15,575,221) $ (12,167,104)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization     7,636 7,636  
Depreciation     45,678 45,678  
Share-based compensation 285,856 285,093 580,542 552,064  
Share of loss on equity investment 61,993 42,584 106,823 114,099  
Change in fair value of warrants (211,777) (806,841) (142,576) (190,198)  
Changes in working capital:          
Decrease in amounts receivable and prepaid expenses     97,462 642,846  
Decrease in accounts payable     (1,404,056) (2,167,542)  
Increase in accrued expenses and other payables     611,618 287,223  
Total cash flow from operating activities     (15,672,094) (12,875,298)  
Cash flows from Investing activities          
Proceeds from short term investments     7,372,473  
Equity investment in BC Therapeutics     (165,000) (150,000)  
Total cash flow from investing activities     7,207,473 (150,000)  
Cash flows from financing activities          
Proceeds from exercise of warrants     821,015  
Proceeds from the issuance of shares, net of issuance costs     27,874,441 16,355,848  
Total cash flow from financing activities     27,874,441 17,176,863  
Increase in cash and cash equivalents     19,409,820 4,151,565  
Cash and cash equivalents at beginning of the period     10,493,808 862,089 $ 862,089
Cash and cash equivalents at end of the period $ 29,903,628 $ 5,013,654 $ 29,903,628 $ 5,013,654 $ 10,493,808